Medications ›orforglipron

orforglipron

RxCUI 2739838 ingredient

Contraindicated with · 25

Diagnoses16

Carcinoma, Medullary Multiple Endocrine Neoplasia Type 2b Multiple Endocrine Neoplasia Multiple Endocrine Neoplasia Type 2a Neoplasms, Multiple Primary Carcinoma, Neuroendocrine Neoplastic Syndromes, Hereditary Neoplasms, Ductal, Lobular, and Medullary Adenocarcinoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Nerve Tissue Carcinoma Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Genetic Diseases, Inborn

Condition families9

Thyroid Neoplasms Head and Neck Neoplasms Endocrine Gland Neoplasms Thyroid Diseases Neoplasms by Histologic Type Endocrine System Diseases Neoplasms by Site Congenital, Hereditary, and Neonatal Diseases and Abnormalities Neoplasms

Indicated for · 8

Diagnoses4

Obesity Overnutrition Overweight Body Weight

Condition families4

Nutrition Disorders Nutritional and Metabolic Diseases Signs and Symptoms Pathological Conditions, Signs and Symptoms

MED-RT, published by the VA through NLM. Relationships attach at the ingredient level, not to a specific product or dose.

RADV audits Coding jobs Chart counter Hours & decimal time About Contact Help Terms Privacy

Innova Coding Suite extension — both tools in your browser: Add to Chrome · Add to Edge

InnovaRx — Innova Health Strategies. ICD-10-CM and the CMS-HCC risk adjustment models are published by CMS and NCHS and are in the public domain. Effective date 2026-10-22 travels in the URL, so this link shows anyone exactly what you see.